Deepa R Pakianathan

Dr. Pakianathan currently serves as Chief Executive Officer of a stealth mode company developing drugs for autoimmune diseases and as a Managing Member at Delphi Ventures, a venture capital firm focusing on healthcare investments. Prior to joining Delphi, Dr. Pakianathan served as a Vice President in the healthcare group at JP Morgan Chase & Company from 1998-to 2001. Before joining JP Morgan, Dr. Pakianathan served as a research analyst at Genesis Merchant Group and prior to that as a postdoctoral scientist in the Immunology Department at Genentech. Dr. Pakianathan currently serves on the board of directors of Theravance Biopharma, Karyopharm Therapeutics, Mereo BioPharma PLC, Palleon Pharmaceuticals, and FS Development Corp II, a publicly-traded SPAC. Dr. Pakianathan holds an M.S. and a Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India, and an M.Sc. from The Cancer Research Institute at the University of Bombay, India.